Wuxi Biologics Shares Slide on Lower Profit Guidance
By Ben Otto
Shares of Wuxi Biologics (Cayman) were halted in Hong Kong after sliding 24% on guidance for lower profit and weaker-than-expected revenue.
The Chinese contract drugmaker's shares were down to 33.15 Hong Kong dollars (US$4.24) on Monday, on track for their biggest one-day slide since listing in 2017. The stock has fallen 45% this year.
The drop came after Wuxi Biologics said it expects a weaker bottom line this year due mainly to spending on capacity expansion and lower revenue growth.
Revenue growth will fall short of a 30% target, with 40 fewer projects meaning a revenue gap of about US$300 million and delays in regulatory approval affecting an additional US$100 million, it said in presentation slides on its website.
A goal to add 120 new projects this year was "overtly bullish," it said. The company added 91 new projects through November, compared with 138 and 136 for 2021 and 2022, respectively.
"Our industry faces near-term challenges," with a biotech funding slowdown likely leading to annual growth in the single digits, down from a rate of around 15% in past years, Wuxi Biologics said.
It said its gross profit margin and growth rate likely bottomed out this year and forecast a turnaround in the second half of 2024.
The Wuxi, China-based company posted first-half revenue of 8.49 billion yuan (US$1.19 billion), up 18% from a year earlier, while profit fell 11% to CNY2.27 billion.
Write to Ben Otto at ben.otto@wsj.com
(END) Dow Jones Newswires
December 03, 2023 23:07 ET (04:07 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks